Association of enkephalin catabolism inhibitors and CCK-B antagonists: A potential use in the management of pain and opioid addiction

Neurochemical Research

Volumn 21, Issue 11, 1996, Pages 1397-1410

  Roques, Bernard P ^a   Noble, Florence ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

addiction; CCK B antagonists; cholecystokinin; Endogenous enkephalins; pain; peptidase inhibitors

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMINOPEPTIDASE; BC 264; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DELTA OPIATE RECEPTOR; DEVAZEPIDE; ENKEPHALIN; ENKEPHALINASE INHIBITOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENZYME INHIBITOR; KELATORPHAN; LEUCINE ENKEPHALIN[2 DEXTRO O TERT BUTYLSERINE 6 O TERT BUTYLTHREONINE]; METHADONE; MORPHINE; N [1 [(2,2 DIMETHYL 1,3 DIOXOLAN 4 YL)METHOXYCARBONYL] 2 PHENYLETHYL]PHENYLALANYL BETA ALANINE; N [2 BENZYL 3 [(HYDROXYAMINO)CARBONYL]PROPIONYL]PHENYLALANINE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; NALOXONE; NALTRINDOLE; PROGLUMIDE; THIORPHAN; UNCLASSIFIED DRUG;

ANALGESIA; ANTINOCICEPTION; ARTICLE; DRUG POTENTIATION; DRUG TOLERANCE; HOT PLATE TEST; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; OPIATE ADDICTION; PAIN; PRIORITY JOURNAL; REWARD; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

EID: 0029958717     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02532381     Document Type: Article

References (117)

1. 3H-etorphin to rat brain homogenate. Proc. Natl. Acad. Sci. USA 70:1947-1949.
2. Pert, C. B., and Snyder, S. H. 1973. Opiate receptor: demonstration in nervous tissue. Science 179:1011-1014.
3. Terenius, L. 1973. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat brain cortex. Acta Pharmacol. Toxicol. 32:317-320.
4. Hughes, J., Smith, T. W., Kosterlitz, H. W., Fotherghill, L. A., Morgan, B. A., and Morris, H. R. 1975. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (Lond.) 258:577-579.
5. Young, E., Bronstein, D., and Akil, H. 1993. Proopiomelanocortin biosynthesis, processing and secretion: functional implications. Pages 393-421, in Herz, A., Akil, H., and Simon, E. J. (eds.), Handbook of Experimental Pharmacology, Opioids I, Springer-Verlag, Berlin, Heidelberg.
6. Rossier, J. 1993. Biosynthesis of enkephalins and proenkephalin-derived peptides. Pages 423-447, in Herz, A., Akil, H., and Simon, E. J. (eds.), Handbook of Experimental Pharmacology, Opioids I, Springer-Verlag, Berlin, Heidelberg.
7. Day, R., Trujillo, K. A., and Akil, H. 1993. Prodynorphin biosynthesis and posttranslational processing. Pages 449-470, in Herz, A., Akil, H., and Simon, E. J. (eds.), Handbook of Experimental Pharmacology, Opioids I, Springer-Verlag, Berlin, Heidelberg.
8. Besse, D., Lombard, M. C., Zajac, J. M., and Roques, B. P. 1990. Pre- and postsynaptic distribution of μ, δ and κ opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res. 521:15-22.
9. Galina, Z. H., and Kastin, A. J. 1986. Existence of anti-opiate systems as illustrated by MIF-1/Tyr-MIF-1. Life Sci. 39:2153-2159.
10. Paris, P. L., Komisaruk, B. R., Watkins, L. R., and Mayer, D. J. 1983. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219:310-312.
11. 2-like immunoreactivity. Proc. Natl. Acad. Sci. USA 81:5002-5005.
12. Meunier, J. C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J. L., Guillemot, J. C., Ferrara, P., Monsarrat, B., Mazarguil, H., Vassart, G., Parmentier, M., and Costentin, J. 1995. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-535.
13. Reinscheid, R. K., Nothacker, H. P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, Jr., F. J., and Civelli, O. 1995. Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science 270:792-794.
14. Roques, B. P., Noble, F., Daugé, V., Fournié-Zaluski, M. C., and Beaumont, A. 1993. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45:87-146.
15. Crawley, J. N., and Corwin, R. L. 1994. Biological actions of cholecystokinin. Peptides 15:731-755.
16. Olson, G. A., Olson, R. D., and Kastin, A. J. 1995. Endogenous opiates: 1994. Peptides 16:1517-1556.
17. Vanderhaeghen, J. J., Signeau, J. C., and Gepts, W. 1975. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature (Lond.) 257:604-605.
18. Moran, T. H., Robinson, P. H., Goldrich, M. S., and McHugh, P. R. 1986. Two brain cholecystokinin receptors: implication for behavioral actions; Brain Res. 362:175-179.
19. Kopin, A. S., Lee, Y. M., McBride, E. W., Miller, L. J., Lu, M., Lin, H. Y., and Kolakowski Jr., L. F. 1992. Expression, cloning and characterization of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. USA 89:3605-3609.
20. Wank, S. A., Harkins, R., Jensen, R. T., Shapira, H., Weerth, A., and Slattery, T. 1992. Purification, molecular cloning and functional expression of the cholecystokinin receptor from rat pancreas. Proc. Natl. Acad. Sci. USA 89:3125-3129.
21. Lee, Y. M., Beinborn, M., McBride, E. W., Lu, M., Kolakowski Jr., L. F., and Kopin, A. S. 1993. The human brain cholecystokinin-B/gastrin receptor. J. Biol. Chem. 268:8164-8169.
22. Gall, C., Lauterborn, J., Burks, D., and Seroogy, K. 1987. Colocalization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res. 403:403-408.
23. 5-enkephalin-, and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J. Neurochem. 55:1122-1130.
24. Baber, N. S., Dourish, C. T., and Hill, D. R. 1989. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39: 307-328.
25. Noble, F., Derrien, M., and Roques, B. P. 1993. Modulation of opioid analgesia by CCK at the supraspinal level. Evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmacol. 109:1064-1070.
26. Miller, K. K., and Lupica, C. R. 1994. Morphine-induced excitation of pyramidal neurons is inhibited by cholecystokinin in the CA1 region of the rat hippocampal slice. J. Pharmacol. Exp. Ther. 268:753-761.
27. Valverde, O., Maldonado, R., Fournié-Zaluski, M. C., and Roques, B. P. 1994. Cholecystokinin B antagonist strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmacol. Exp. Ther. 270:77-88.
28. Liu, N. J., Xu, T., Xu, C., Li, C. Q., Yu, Y. X., Kang, H. G., and Han, J. S. 1995. Cholecystokinin octapeptide reverses μ-opioid-receptor-mediated inhibition of calcium current in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. 275:1293-1299.
29. Roques, B. P., Fournié-Zaluski, M. C., Soroca, E., Lecomte, J. M., Malfroy, B., Llorens, C., and Schwartz, J. C. 1980. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature (Lond.) 288:286-288.
30. Fournié-Zaluski, M. C., Coric, P., Turcaud, S., Lucas, E., Noble, F., Maldonado, R., and Roques, B. P. 1992. Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J. Med. Chem. 35:2473-2481.
31. Noble, F., Soleilhac, J. M., Soroca-Lucas, E., Turcaud, S., Fournié-Zaluski, M. C., and Roques, B. P. 1992. Inhibition of the enkephalin metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 261:181-190.
32. Delay-Goyet, P., Zajac, J. M., and Roques, B. P. 1989. Effects of repeated treatment with haloperidol on rat striatal neutral endopeptidase EC 3.4.24.11, and on μ and δ opioid binding sites: comparison with chronic morphine and chronic kelatorphan. Neurosci. Lett. 103:197-202.
33. Roques, B. P. 1988. Physiological role of endogenous peptide effectors studies with peptidase inhibitors. Kidney Int. 34:S27-S33.
34. Roques, B. P., and Noble, F. 1995. Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Pages 104-145, in Rapaka, R. S., and Sorer, H. (eds.), NIDA Research Monograph 147, Discovery of Novel Opioid Medications, NIH Publication.
35. Aghajanian, G. K. 1978. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature (Lond.) 276:186-188.
36. Williams, J. T., Christie, M. J., North, R. A., and Roques, B. P. 1987. Potentiation of enkephalin action by peptidase inhibitors in rat locus coeruleus in vitro. J. Pharmacol. Exp. Ther. 243: 186-188.
37. Duman, R. S., Tallman, J. F., and Nestler, E. J. 1988. Acute and chronic opiate regulation of adenylate cyclase in brain: specific effects in locus coeruleus. J. Pharmacol. Exp. Ther. 246:1033-1039.
38. Maldonado, R., Stinus, L., Gold, L. H., and Koob, G. F. 1992. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261: 669-677.
39. Noble F., and Roques, B. P. 1995. Assessment of endogenous enkephalins efficacy in the hot plate test in mice: comparative study with morphine. Neurosci. Lett. 185:75-78.
40. Abbadie, C., Honoré, P., Fournié-Zaluski, M. C., Roques, B. P., and Besson, J. M. 1994. Effects of opioids and non-opioids on c-Fos-like immunoreactivity induced in rat lumbar spinal cord neurons by noxious heat stimulation. Eur. J. Pharmacol. 258: 215-227.
41. Tolle, T. R., Schadrack, J., Castro-Lopes, J. M., Evan, G., Roques, B. P., and Zieglgänsberger, W. 1994. Effects of kelatorphan and morphine before and after noxious stimulation on immediate-early gene expression in rat spinal cord neurons. Pain 56:103-112.
42. Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J., and Schütz, G. 1996. A mutation in the CREB gene strongly reduces the withdrawal syndrome in morphine dependent mice. Science, 273:657-659.
43. Matsuoka, I., Maldonado, R., Defer, N., Nöel, F., Hanoune, J., and Roques, B. P. 1994. Chronic morphine administration causes region-specific increase of brain type VIII adenylyl cyclase mRNA. Eur. J. Pharmacol. (Mol. Pharmacol. Sec.) 268:215-221.
44. Faris, P. L., McLaughlin, C. L., Baile, C. A., Olney, J. W., and Komisaruk, B. R. 1984. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 226:1215-1217.
45. Watkins, L. R., Kinscheck, I. B., Kaufman, E. F. S., Miller, J., Frenk, H., and Mayer, D. J. 1985. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res. 327:181-190.
46. Dourish, C. T., Clark, M. L., and Iversen, S. D. 1988. Analgesia induced by restrain stress is attenuated by CCK and enhanced by the CCK antagonist MK-329, L-365,260 and CR-1409. Soc. Neurosci. Abstr. 14:120.
47. Hendrie, C. A., Shepherd, J. K., and Rodgers, R. J. 1989. Differential effects of the CCK antagonist, MK 329, on analgesia induced by morphine, social conflict (opioid) and defeat experience (non-opioid) in male mice. Neuropharmacology 28:1025-1032.
48. Ruiz-Gayo, M., Daugé, V., Menant, I., Begue, D., Gacel, G., and Roques, B. P. 1985. Synthesis and biological activity of Boc(Nle28-31)CCK7 a highly potent CCK analog. Peptides 6:415-120.
49. Charpentier, B., Durieux, C., Pélaprat, D., Dor, A., Reibaud, M., Blanchard, J. C., and Roques, B. P. 1988. Enzyme resistant CCK analogs with high affinities for central receptors. Peptides 9:835-841.
50. 8) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors. Neuropharmacology 26:289-300.
51. 2 with μ and δ opioid antinociception in the rat spinal cord. Neuropeptides 16:213-218.
52. Rattray, M., and De Belleroche, J. 1987. Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: sensitisation by naloxone. Neuropeptides 10:189-200.
53. Rodriguez, R. E., and Sacristan, M. P. 1989. In vivo release of CCK-8 from the dorsal horn of the rat: inhibition by DAGOL. FEBS Lett. 250:215-217.
54. Benoliel, J. J., Bourgoin, S., Mauborgne, A., Legrand, J. C., Hamon, M., and Cesselin, F. 1991. Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation. Neurosci. Lett. 124:204-207.
55. Benoliel, J. J., Mauborgne, A., Bourgoin, S., Legrand, J. C., Hamon, M., and Cesselin, F. 1992. Opioid control of the in vitro release of CCK-like material from the rat substantia nigra. J. Neurochem. 58:916-922.
56. 3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J. Neurochem. 59:1805-1811.
57. Maldonado, R., Derrien, M., Noble, F., and Roques, B. P. 1993. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive response. NeuroReport 4:947-950.
58. Valverde, O., Blommaert, A. G. S., Fournié-Zaluski, M. C., Roques, B. P., and Maldonado, R., 1995. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCK-B receptor antagonist. Eur. J. Pharmacol. 286:79-93.
59. Noble, F., Blommaert, A., Fournié-Zaluski, M. C., and Roques, B. P. 1995. A selective CCK-B receptor antagonist potentiates μ-, but not δ-opioid receptor-mediated antinociception in the formalin test. Eur. J. Pharmacol. 273:145-151.
60. Wang, X. J., Wang, X. H., and Han, J. S. 1990. Cholecystokinin octapeptide antagonized opioid analgesia mediated by μ- and κ-but not δ-receptors in the spinal cord of the rat. Brain Res. 523: 5-10.
61. Wang, X. J., and Han, J. S. 1990. Modification by cholecystokinin octapeptide of the binding of μ, δ- and κ-opioid receptors. J. Neurochem. 55:1379-1382.
62. Noble, F., Smadja, C., and Roques, B. P. 1994. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists. J. Pharmacol. Exp. Ther. 271:1127-1134.
63. Portoghese, P. S., Nagase, H., MaloneyHuss, K. E., Lin, C. E., and Takemori, A. E. 1991. Role of spacer and address components in peptidomimetic δ opioid receptor antagonists related to naltrindole. J. Med. Chem. 34:1715-1720.
64. 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur. J. Pharmacol. 218:195-196.
65. 2 opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for δ opioid receptor heterogeneity. Neuroscience, In press.
66. Kamei, J., Iwamoto, Y., Suzuki, T., Nagase, H., Misawa, M., and Kasuya, Y. 1993. Differential modulation of μ-opioid receptor-mediated antitussive activity by δ-opioid receptor agonists in mice. Eur. J. Pharmacol. 234:117-120.
67. Attal, N., Desmeules, J., Kayser, V., Jazat, F., and Guilbaud, G. 1991. Effects of opioids in a rat model of peripheral mononeuropathy. Pages 245-258, in Besson, J. M., and Guilbaud, G. (eds.), Lesions of primary afferent fibers as a tool for the study of clinical pain, Elsevier Science Publishers, Amsterdam.
68. Foley, K. M. 1993. Opioid analgesics in clinical pain management. Pages 697-743, in Herz, A., Akil, H., and Simon, E. J. (eds.), Handbook of Experimental Pharmacology, Opioids II, Springer-Verlag, Berlin, Heidelberg.
69. Hökfelt, T., Xu, Z., Verge, V., Villar, M., Elde, R., Xu, X. J., and Wiesenfeld-Hallin, Z. 1994. Messenger plasticity in primary sensory neurons. Pages 71-84, in Hökfelt, T., Schaible, H. G., and Schmidt, R. F. (eds.), Neuropeptides, Nociception, and Pain, Chapman and Hall, Weinheim.
70. Verge, V. M. K., Wiesenfeld-Hallin, Z., and Hökfelt, T. 1993. Cholecystokinin in mammalian primary sensory neurons and spinal cord: in situ hybridization studies on rat and monkey spinal ganglia. Eur. J. Neurosci. 5:240-250.
71. Stanfa, L., Dickenson, A., Xu, X. J., and Wiesenfeld-Hallin, Z. 1994. Cholecystokinin and morphine analgesia. Trends Pharmacol. Sci. 15:65-66.
72. Xu, X. J., Puke, M. J. C., Verge, V. M. K., Wiesenfeld-Hallin, Z., Hughes, J., and Hökfelt, T. 1993. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci. Lett. 152:129-132.
73. Nichols, M. L., Bian, D., Ossipov, M. H., Lai, J., and Porreca, F. 1995. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neurophatic pain in rats. J. Pharmacol. Exp. Ther. 275:1339-1345.
74. Xu, X. J., Hökfelt, T., Hughes, J., and Wiesenfeld-Hallin, Z. 1994. The CCK-B antagonist CI 988 enhances the reflex-depressive effect of morphine in axotomized rats. NeuroReport 5: 718-720.
75. Xu, X. J., Hao, J. X., Seiger, A., Hughes, J., Hökfelt, T., and Wiesenfeld-Hallin, Z. 1994. Chronic pain-related behaviors in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain 56:271-277.
76. Maldonado, R., Féger, J., Fournié-Zaluski, M. C., and Roques, B. P. 1990. Differences in physical dependence induced by selective μ or δ opioid agonists and by endogenous enkephalins protected by peptidase inhibitors. Brain Res. 520:247-254.
77. Zhou, Y., Sun, Y. H., Zhang, Z. W., and Han, J. S. 1992. Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. NeuroReport 3:1121-1123.
78. Pu, S. F., Zhuang, H. X., Lu, Z. B., Wu, X. R., and Han, J. S. 1994. Cholecystokinin gene expression in rat amygdaloid neurons. Normal distribution and effect of morphine tolerance. Mol. Brain Res. 21:183-189.
79. Pohl, M., Collin, E., Benoliel, J. J., Bourgoin, S., Cesselin, F., and Hamon, M. 1992. Cholecystokinin (CCK)-like material and CCK mRNA levels in the rat brain and spinal cord after acute or repeated morphine treatment. Neuropeptides 21:193-200.
80. Panerai, A. E., Rovati, L. C., Cocco, E., Sacerdote, P., and Montegazza, P. 1987. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin. Brain. Res. 410: 52-60.
81. Dourish, C. T., O'Neill, M. F., Couglan, J., Kitchener, S. J., Hawley, D., and Iversen, S. D. 1990. The selective CCK-B antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in rat. Eur. J. Pharmacol. 175:35-44.
82. Xu, X. J., Wiesenfeld-Hallin, Z., Hughes, J., Horwell, D. C., and Hökfelt, T. 1992. CI 988, a selective antagonist of cholecystokinin-B receptors, prevents morphine tolerance in rats. Br. J. Pharmacol. 105:591-596.
83. Hoffmann, O., and Wiesenfeld-Hallin, Z. 1994. The CCK-B receptor antagonist CI 988 reverses tolerance to morphine in rats. NeuroReport. 5:2565-2568.
84. Pournaghash, S., and Riley, A. 1991. Failure of cholecystokinin to precipitate withdrawal in morphine-treated rats. Pharmacol. Biochem. Behav. 38:479-484.
85. Maldonado, R., Valverde, O., Derrien, M., Tejedor-Real, P., and Roques, B. P. 1994. Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats. Pharmacol. Biochem. Behav. 48:363-369.
86. Bozarth, M. A., and Wise, R. A. 1984. Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 224:516-517.
87. 5-enkephalinamide into the ventral tegmental area. Behav. Brain Res. 5:225-229.
88. Bozarth, M. A. 1986. Neural basis of psychomotor stimulant and opiate reward: evidence suggesting the involvement of a common dopaminergic system. Behav. Brain Res. 22:107-116.
89. Cador, M., Taylor, J. R., and Robbins, T. W. 1991. Potentiation of the effects of reward-related stimuli by dopaminergic-dependent mechanisms in the nucleus accumbens. Psychopharmacology 104:377-385.
90. 8 and of the CCK-B selective agonist BC 264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res. 628:254-262.
91. Higgins, G. A., Nguyen, P., and Sellers, E. M. 1991. Blockade of morphine conditioning by the CCK-A receptor antagonist devazepide. Eur. J. Pharmacol. 197:229-230.
92. Higgins, G. A., Nguyen, P., and Sellers, E. M. 1992. Morphine place conditioning is differentially affected by CCK-A and CCK-B receptor antagonists. Brain Res. 572:208-215.
93. Glimcher, P. W., Giovino, A. A., Margolin, D. H., and Hoebel, B. G. 1984. Endogenous opiate reward induced by an enkephalinase inhibitor, thiorphan, injected into the ventral midbrain. Behav. Neurosci. 98:262-268.
94. Agmo, A., Gomez, M, and Irazabal, Y. 1994. Enkephalinase inhibition facilitates sexual behavior in the male rat, but does not produce conditioned place preference. Pharmacol. Biochem. Behav. 47:771-778.
95. Noble, F., Fournié-Zaluski, M. C., and Roques, B. P. 1993. Unlike morphine, the endogenous enkephalins protected by RB 101 are unable to establish a conditioned place preference in mice. Eur. J. Pharmacol. 230:139-149.
96. Valverde, O., Fournié-Zaluski, M. C., Roques, B. P., and Maldonado, R. 1996. The CCK-B antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats. Psychopharmacology 123:119-126.
97. Higgins, G. A., Joharchi, N., Wang, Y., Corrigall, W. A., and Sellers, E. M. 1994. The CCK-A receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol. Brain Res. 640:246-254.
98. Bhargava, H. N. 1994. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administrative behavior. Pharmacol. Rev. 46:293-324.
99. Kreek, M. J., and Hartman, N. 1982. Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity. Ann. N.Y. Acad. Sci. 398:151-172.
100. Hutcheson, D. M., Maldonado, R., Roques, B. P., Fache, D. M., and Sewell, R. D. E. 1995. Effects of the mixed inhibitor of enkephalin catabolism, RB 101 on naloxone-induced morphine withdrawal conditioned place aversion. Analgesia 1:477-480.
101. Waksman, G., Hamel, E., Fournié-Zaluski, M. C., and Roques, B. P. 1986. Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain. Proc. Natl. Acad. Sci. USA 83: 1523-1527.
102. Laschka, E., Teschemacher, H., Mehrain, P., and Herz, A. 1976. Sites of action of morphine involved in the development of physical dependence in rats. Psychopharmacologia (Berl.) 46:141-147.
103. Maldonado, R., Fournié-Zaluski, M. C., and Roques, B. P. 1992. Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter. Naunyn-Schmied. Arch. Pharmacol. 345:466-472.
104. Maldonado, R., Valverde, O., Ducos, B., Blommaert, A. G., Fournié-Zaluski, M. C., and Roques, B. P. 1995. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCK-B antagonist PD-134,308. Br. J. Pharmacol. 114:1031-1039.
105. Ruiz, F., Fournié-Zaluski, M. C., Roques, B. P., and Maldonado, R. 1996. The inhibitor of enkephalin catabolism, RB 101, induces a decrease, similar to methadone, in spontaneous morphine abstinence in rats. Br. J. Pharmacol. in press.
106. 1 dopamine receptor gene. Proc. Natl. Acad. Sci. USA 88:4205-4209.
107. Roques, B. P., Daugé, V., Gacel, G., and Fournié-Zaluski, M. C. 1985. Selective agonists and antagonists of delta opioid receptors and inhibitors of enkephalin metabolism: potential use in treatment of mental illness. Pages 287-289, in Shagass, C., Josiassen, R. C., Bridger, H. W., Weiss, K. J., Stoff, D., and Simpson, G. M. (eds.), Biological Psychiatry, Developments in Psychiatry Vol. 7, Elsevier, New-York.
108. Ben Natan, L., Chaillet, P., Lecomte, J. M., Marçais, H., Uchida, G., and Costentin, J. 1984. Involvement of endogenous enkephalins in the mouse "behavioral despair" test. Eur. J. Pharmacol. 97:301-304.
109. Lecomte, J. M., Costentin, J., Vlaiculescu, A., Chaillet, P., Marçais-Collado, H., Llorens-Cortes, C., Leboyer, M., and Schwartz, J. C. 1986. Pharmacological properties of acetorphan, a parenterally active enkephalinase inhibitor. J. Pharmacol. Exp. Ther. 237:937-944.
110. Gibert-Rahola, J., Tejedor, P., Chover, A. J., Payana, M., Rodriguez, M. M., Leonsegui, I., Mellado, M., Mico, J. A., Maldonado, R., and Roques, B. P. 1990. RB 38B, a selective endopeptidase inhibitor, induced reversal of escape deficits cause by inescapable shocks pretreatment in rats. Eur. J. Pharmacol. 183:2317-2325.
111. Tejedor-Real, R., Mico, J. A., Maldonado, R., Roques, B. P., and Gibert-Rahola, J. 1993. Effect of a mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin-degrading enzymes on a model of depression in the rat. Biol. Psychiatry 34:100-107.
112. 1 receptor stimulation. Eur. J. Pharmacol. 216:157-166.
113. Smadja, C., Maldonado, R., Turcaud, S., Fournié-Zaluski, M. C., and Roques, B. P. 1995. Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin-antide-pressant-like effects. Psychopharmacology 120:400-408.
114. Crawley, J. N. 1991. Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci. 12:232-236.
115. 8 in the posterior part of the nucleus accumbens. Brain Res. 617:181-188.
116. Derrien, M., Durieux, M., and Roques, B. P. 1994. Antidepressant-like effects of CCK-B antagonists in mice: antagonism by naltrindole. Br. J. Pharmacol. 111:956-960.
117. Hernando, F., Fuentes, J. A., Roques, B. P., and Ruiz-Gayo, M. 1994. The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur. J. Pharmacol. 261:257-263.